This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

BioProcess International

Registration Savings Offer Expires In:

  • 00
  • 00
  • 00
  • 00
September 23-26, 2024
Hynes Convention CenterBoston, USA

Lior Shaltiel
CEO at NurExone Biologic


Dr. Lior Shaltiel is a awarded executive and scientist with a wealth of multidisciplinary international experience, specializing in innovative drug delivery systems. Since 2021, serving as the CEO and Director at NurExone Biologic Inc., an Canadian-Israeli biopharmaceutical company (TSXV:NRX) (OTCQB: NRXBF) at the forefront of utilizing advanced exosome technologies for the treatment of Spinal Cord Injury and CNS indications through minimally invasive administration.

In 2015, Dr. Shaltiel founded and currently leads as the Academic Head of the BioMed-MBA program at the Hebrew University Business School (HUBS), where he bridges academic knowledge with entrepreneurial success. With a strong background in the industry, Dr. Shaltiel leverages his expertise to seize investment opportunities. Recently, he assumed the role of Co-Chairman of the MedTech division at the Israeli Association of Engineers, further solidifying his commitment to innovation and advancement in the field and the ecosystem.

Agenda Sessions

  • From Antibodies to EVs and siRNA Therapy: A Comparative Analysis of AbbVie and NurExone's approaches to Effective Spinal Cord Injury Treatment

  • Beyond mAbs: The Next Wave of Therapeutic Innovation for a New Era